1. Home
  2. BXMX vs ATAI Comparison

BXMX vs ATAI Comparison

Compare BXMX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

BXMX

Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

HOLD

Current Price

$14.01

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$3.66

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXMX
ATAI
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BXMX
ATAI
Price
$14.01
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$15.57
AVG Volume (30 Days)
142.4K
4.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$308,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$285.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.25
$1.15
52 Week High
$15.00
$6.73

Technical Indicators

Market Signals
Indicator
BXMX
ATAI
Relative Strength Index (RSI) 37.93 46.06
Support Level $13.70 $3.41
Resistance Level $14.02 $4.32
Average True Range (ATR) 0.21 0.25
MACD -0.06 -0.00
Stochastic Oscillator 15.00 27.82

Price Performance

Historical Comparison
BXMX
ATAI

About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: